
Clearside Biomedical CLSD
Quarterly report 2025-Q3
added 11-14-2025
Clearside Biomedical General and Administrative Expenses 2011-2025 | CLSD
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Clearside Biomedical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.9 M | 11.8 M | 11.7 M | 10.8 M | 16.8 M | 14.7 M | 9.7 M | 6.26 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 16.8 M | 6.26 M | 11.7 M |
Quarterly General and Administrative Expenses Clearside Biomedical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.1 M | 2.48 M | 2.82 M | - | 2.84 M | 3.08 M | 2.82 M | - | 2.64 M | 3.13 M | 3.16 M | - | 2.35 M | 2.79 M | 3.46 M | - | 2.82 M | 2.82 M | 2.89 M | - | 2.37 M | 2.61 M | 3.12 M | - | 3.78 M | 5 M | 4.38 M | - | 3.87 M | 3.56 M | 3.07 M | - | 2.3 M | 2.29 M | 2.67 M | - | 1.63 M | 970 K | 1.27 M | - | 1.06 M | 3.02 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5 M | 970 K | 2.76 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
22.5 M | $ 4.76 | -0.52 % | $ 790 M | ||
|
Aclaris Therapeutics
ACRS
|
22.2 M | $ 3.03 | -0.49 % | $ 234 M | ||
|
Aeglea BioTherapeutics
AGLE
|
45.8 M | - | - | $ 1.01 B | ||
|
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
3.05 M | $ 0.22 | 19.47 % | $ 479 M | ||
|
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
5.41 M | $ 1.16 | -0.85 % | $ 6.33 M | ||
|
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | ||
|
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | ||
|
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M | ||
|
Celldex Therapeutics
CLDX
|
38.5 M | $ 26.44 | -1.45 % | $ 1.7 M | ||
|
Cellectar Biosciences
CLRB
|
11.7 M | $ 2.52 | -8.69 % | $ 30.8 M | ||
|
Ascendis Pharma A/S
ASND
|
160 M | $ 209.24 | -1.68 % | $ 5 B | ||
|
Aptevo Therapeutics
APVO
|
10.2 M | $ 0.58 | -37.95 % | $ 160 K | ||
|
Alterity Therapeutics Limited
ATHE
|
5.51 M | $ 3.12 | 0.81 % | $ 7.51 B | ||
|
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | ||
|
BioVie
BIVI
|
8.57 M | $ 1.24 | -2.4 % | $ 1.83 M | ||
|
Athersys
ATHX
|
20.1 M | - | 3.77 % | $ 22.4 M | ||
|
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - | ||
|
Avenue Therapeutics
ATXI
|
4.64 M | - | -52.27 % | $ 4.45 M | ||
|
ARCA biopharma
ABIO
|
13.1 M | - | 1052.0 % | $ 415 M | ||
|
AVROBIO
AVRO
|
24 M | - | 1083.1 % | $ 745 M | ||
|
Acasti Pharma
ACST
|
7.17 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
73.5 M | - | -15.15 % | $ 60.3 M | ||
|
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | ||
|
BioNTech SE
BNTX
|
286 M | $ 94.45 | -0.61 % | $ 27.2 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
56.7 M | $ 26.93 | 0.43 % | $ 1.3 B | ||
|
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B | ||
|
Dynavax Technologies Corporation
DVAX
|
170 M | $ 15.39 | 0.03 % | $ 2 B | ||
|
Anika Therapeutics
ANIK
|
95.8 M | $ 9.55 | 0.74 % | $ 140 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
5.72 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
95.1 M | - | -7.31 % | $ 87 M | ||
|
bluebird bio
BLUE
|
166 M | - | - | $ 546 M | ||
|
Arena Pharmaceuticals
ARNA
|
126 M | - | -6.81 % | $ 3.04 B | ||
|
Eton Pharmaceuticals
ETON
|
18.9 M | $ 16.89 | -0.59 % | $ 433 M | ||
|
Acer Therapeutics
ACER
|
12.7 M | - | 2.71 % | $ 14 M | ||
|
Evogene Ltd.
EVGN
|
7.25 M | $ 1.02 | -2.38 % | $ 27.9 M | ||
|
Calithera Biosciences
CALA
|
20.9 M | - | -10.95 % | $ 876 K | ||
|
Axon Enterprise
AXON
|
741 M | $ 585.17 | -1.01 % | $ 44.3 B | ||
|
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M | ||
|
Exelixis
EXEL
|
492 M | $ 46.26 | -0.54 % | $ 13.4 B | ||
|
Foghorn Therapeutics
FHTX
|
28.4 M | $ 5.43 | 0.55 % | $ 298 M | ||
|
Aytu BioScience
AYTU
|
17.4 M | $ 2.49 | -1.78 % | $ 15.6 M | ||
|
AstraZeneca PLC
AZN
|
15.2 B | $ 92.61 | 0.17 % | $ 96.9 B | ||
|
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | ||
|
Catalyst Biosciences
CBIO
|
14.7 M | $ 12.32 | -0.44 % | $ 811 M |